Li Liang, Li Chengyin, Zhou Yu, Xu Qi, Wang Zilin, Zhu Xiaoyun, Ba Yuanming
Clinical College of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, China.
Department of Oncology, Hubei Provincial Hospital of TCM, Wuhan, China.
Front Pharmacol. 2020 Sep 15;11:560920. doi: 10.3389/fphar.2020.560920. eCollection 2020.
To evaluate the efficacy of Traditional Chinese Medicine, specifically Jianpi Bushen (JPBS) therapy, for treatment of patients with chronic kidney disease (CKD) anemia.
Randomized controlled trials of JPBS therapy for CKD anemia were searched and selected from seven electronic databases. The Cochrane collaboration tool was used to conduct methodological quality assessment. RevMan v5.3 software was utilized to perform data analysis.
In total, 12 randomized controlled trials with 799 patients met the meta-analysis criteria. The aggregated results indicated that JPBS therapy is beneficial for CKD anemia by improving the clinical efficacy rate [risk ratio (RR) = 1.23, 95% confidence interval (CI): (1.14, 1.33), < 0.00001] and hemoglobin (Hb) [weighted mean difference (WMD) = 9.55, 95% CI: (7.97, 11.14), < 0.00001], serum ferritin (SF) [WMD = 6.22, 95% CI: (2.65, 9.79), = 0.0006], red blood cell (RBC) [WMD = 0.31, 95% CI: (0.24, 0.38), < 0.00001], hematocrit (HCT) [WMD = 2.95, 95% CI: (2.36, 3.54), < 0.00001], serum creatinine (SCr) [WMD = 64.57, 95% CI: (33.51, 95.64), < 0.0001], and blood urea nitrogen (BUN) levels [WMD = 3.76, 95% CI: (2.21, 5.31), 0.00001]. Furthermore, evidence suggests that JPBS therapy is safe and does not increase adverse reactions compared with western medicine (WM) alone.
This study found that JPBS therapy has a positive effect on the treatment of CKD anemia. However, more well-designed, double-blind, large-scale randomized controlled trials are needed to assess the efficacy of JPBS therapy in the treatment of CKD anemic patients.
评估中医健脾补肾（JPBS）疗法治疗慢性肾脏病（CKD）贫血患者的疗效。
从七个电子数据库中检索并筛选关于JPBS疗法治疗CKD贫血的随机对照试验。使用Cochrane协作工具进行方法学质量评估。采用RevMan v5.3软件进行数据分析。
共有12项随机对照试验、799例患者符合荟萃分析标准。汇总结果表明，JPBS疗法通过提高临床有效率[风险比（RR）=1.23，95%置信区间（CI）：（1.14，1.33），P<0.00001]、血红蛋白（Hb）[加权均数差（WMD）=9.55，95%CI：（7.97，11.14），P<0.00001]、血清铁蛋白（SF）[WMD = 6.22，95%CI：（2.65，9.79），P = 0.0006]、红细胞（RBC）[WMD = 0.31，95%CI：（0.24，0. + 38），P<0.00001]、血细胞比容（HCT）[WMD = 2.95，95%CI：（2.36，3.54），P<0.00001]、血清肌酐（SCr）[WMD = 64.57，95%CI：（33.51，95.64），P<0.0001]和血尿素氮（BUN）水平[WMD = 3.76，95%CI：（2.21，5.31），P = 0.00001]，对CKD贫血有益。此外，有证据表明，与单纯西医（WM）相比，JPBS疗法安全且不会增加不良反应。
本研究发现JPBS疗法对CKD贫血治疗有积极作用。然而，需要更多设计良好、双盲、大规模的随机对照试验来评估JPBS疗法治疗CKD贫血患者的疗效。
Zotero 插件
